News and Press Releases
Press releases
Theralase® to Present at ThinkEquity Conference
Press ReleaseTMX Newsfile | Oct 9, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – October 9, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical-stage pharmaceutical company dedicated to ...
Correcting and Replacing: Theralase®Releases Q2 2026 Financial Statements
Press ReleaseTMX Newsfile | Sep 18, 2026 7:00 AM EDT Theralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene...
Theralase® Commences GLP Toxicology Analysis of Rutherrin®
Press ReleaseTMX Newsfile | Sep 15, 2026 7:00 AM EDT Successful completion of GLP toxicology analysis for the intravenous administration of Rutherrin(R) lays the groundwork for regulatory submissions supporting first-in-human clinical development for...
Theralase® Releases Q2 2026 Financial Statements
Press ReleaseTMX Newsfile | Aug 28, 2026 4:36 PM EDT Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline Toronto, Ontario–(Newsfile Corp. – August 28, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OT...
Theralase® Closes C$3.6 Million Brokered Financing
Press ReleaseTMX Newsfile | Aug 24, 2026 5:01 PM EDT Toronto, Ontario–(Newsfile Corp. – August 24, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated ...
Theralase®Announces $5 Million Brokered LIFE Offering
Press ReleaseTMX Newsfile | Aug 10, 2026 5:15 PM EDT Toronto, Ontario–(Newsfile Corp. – August 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to...
Theralase® Grants Stock Options
Press ReleaseTMX Newsfile | Aug 7, 2026 5:25 PM EDT Toronto, Ontario–(Newsfile Corp. – August 7, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to t...
Theralase® Engages Global One Media to Expand Global Investor Awareness
Press ReleaseTMX Newsfile | Aug 4, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – August 4, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to t...
Theralase® Receives Receipt for C$100 Million Base Shelf Prospectus
Press ReleaseTMX Newsfile | Jun 30, 2026 4:30 PM EDT Toronto, Ontario–(Newsfile Corp. – June 30, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to t...
Theralase® Lists Warrants on the TSXV
Press ReleaseTMX Newsfile | Jun 3, 2026 7:00 AM EDT Toronto, Ontario–(Newsfile Corp. – June 3, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to the...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni













